Currently we are trying to define what makes a hemangioma different than other types of hemangiomas. The small information that we’ve gotten so far is that they have different types of receptors within them – namely in the infantile hemangiomas, you have GLUT1 receptors, whereas in the other types of hemangiomas, you don’t. We don’t know what the effect of this is yet except for the fact that we’ve seen that propranolol tends to have a stronger effect on infantile hemangiomas. Otherwise, what we are studying is a large variety of syndromes like Klippel Trenaunay Syndrome. We’re trying to figure out what causes the different parts of the mixed venous malformations or the mixed overall vascular malformations.